NR ANPQ
AU Chaussain,J.L.
TI [Critical analysis of treatments with growth hormones in children]
OT Analyse critique des traitements par l'hormone de croissance chez l'enfant
QU Bulletin de l'Académie Nationale de Médecine 2002; 186(7): 1211-6; discussion 1216-9
PT journal article
AB The history of growth hormone treatments in France has been marked by the tragedy of the epidemy of Creutzfeldt-Jakob disease secondary to the contamination of preparations of extractive growth hormone, administered between 1983 and 1985. The substitution with biosynthetic growth hormone has suppressed this risk and allow the analysis of long term results. It is still too early to evaluate the efficacy in short stature secondary to chronic renal insufficiency and intrauterine growth retardation. In contrast, final heights are actually known in patients with growth hormone deficiency and Turner Syndrome. These adult heights, ranging around - 2 SDS of the normal population, are satisfaisant but not sufficient, pointing out the necessity of an optimization of the treatments. Earlier onset of therapy, best adaptation and increase of the doses are some of the possibilities.
MH Child; English Abstract; Growth Disorders/*drug therapy; Growth Hormone/*therapeutic use; Human
AD Service d'Endocrinologie Pediatrique, Hopital Saint-Vincent-de-Paul, 82 avenue Denfert-Rochereau, 75674 Paris.
SP französisch
PO Frankreich